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Abstract
Bone metastases associated with breast cancer remain a clinical challenge 
due to their associated morbidity, limited therapeutic intervention and lack 
of prognostic markers. With a continually evolving understanding of bone 
biology and its dynamic microenvironment, many potential new targets 
have been proposed. In this chapter, we discuss the roles of well- established 
bone markers and how their targeting, in addition to tumour-targeted thera-
pies, might help in the prevention and treatment of bone metastases. There 
are a vast number of bone markers, of which one of the best-known fami-
lies is the bone morphogenetic proteins (BMPs). This chapter focuses on 
their role in breast cancer-associated bone metastases, associated signalling 
pathways and the possibilities for potential therapeutic intervention. In 
addition, this chapter provides an update on the role receptor activator 
of nuclear factor-κB (RANK), RANK ligand (RANKL) and osteoprote-
gerin (OPG) play on breast cancer development and their subsequent influ-
ence during the homing and establishment of breast cancer- associated bone 
metastases. Beyond the well-established bone molecules, this chapter also 
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explores the role of other potential factors such as activated leukocyte cell 
adhesion molecule (ALCAM) and its potential impact on breast cancer
cells’ affinity for the bone environment, which implies that ALCAM could
be a promising therapeutic target.
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9.1  Introduction
The propensity of breast cancer to metastasise to 
bone is a well-noted phenomenon. In 1889, 
through post-mortem study, Paget [1] identified 
that breast cancer cases were associated with 
bone metastasis. In spite of this observed occur-
rence, clinical intervention remains limited and 
palliative. Breast cancer is the leading cancer in 
females in the UK and the USA and is a common
cause of cancer-related deaths. The most com-
mon metastatic site is the bone, and 50–70% of 
patients develop bone metastases [2]. Though the 
survival rate of breast cancer patients diagnosed 
with bone metastases varies greatly in the litera-
ture, depending on if it is bone metastases alone 
or in combination with visceral metastasis (up to 
72 months [3]), only 30% of these women are 
expected to achieve 5-year survival after their 
bone metastasis diagnosis [4].
The metastatic cascade is not a new concept, 
and the process is highly inefficient, with only 
0.001–0.02% of cancer cells forming metastatic 
foci [5] of which, our understanding of the bio-
logical drivers remains poor. With the success of 
first-line therapies, breast cancer patients are sur-
viving longer. However, the bone marrow pro-
vides a niche for metastasising breast cancer 
cells, which can be activated many years later. 
Evidence has shown that tumour cells are detect-
able in patient bone marrow, but these do not 
always result in metastatic foci due to a variety of 
factors including tumour cell dormancy or host 
response [6, 7]. A better understanding of what 
reactivates these cancer cells and their interplay, 
both mechanically and biologically, which occurs 
between the bone environment and these cells, is 
fundamental to future identification of patients 
most at risk of developing bone metastases and 
development of novel therapeutic interventions.
The bone is a dynamic tissue which not only 
provides structural support and protection but 
also acts as a reservoir for haematopoietic 
cells and an elaborate blood supply. As meta-
static breast cancer cells colonise the bone envi-
ronment utilising growth factors, such as 
transforming growth factor β (TGF-β) and 
insulin- like growth factors, to stimulate tumour 
growth and they also feedback into the bone envi-
ronment through direct cell-to-cell contact and 
paracrine influence. Tumour cells secrete a range 
of factors, including interleukins, tumour necro-
sis factor (TNF)-alpha and parathyroid hormone-
related protein (PTHrP), both osteo-inductive 
factors, which influence the physiological bone 
environment, enable tumour growth and stimu-
late osteoclastogenesis [8]. This bidirectional 
signalling and co-operation are referred to as the 
‘vicious cycle’ and involve bone remodelling 
cells such as osteoclasts and osteoblasts, as well 
as the recruitment and modulation of other cell 
types including platelets, immune and nerve 
cells, which can further facilitate pro-tumorigenic 
processes, including angiogenesis [9–11].
The nature of bone metastases are heteroge-
neous ranging from bone destructing (osteolytic) 
to bone forming (osteoblastic), with potential for 
both cases to also occur at the same time (mixed 
lesions). Within breast cancer, it is the osteolytic 
phenotype which is frequently observed. 
Bisphosphonates, which bind to bone mineral 
and result in osteoclast apoptosis, and receptor 
activator of NF-κB ligand (RANKL)-targeted 
antibodies remain the main standard of care for 
skeletal-related events (SREs) occurring in 
breast cancer patients with bone metastases [12]. 
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These interventions currently reduce the mor-
bidities which are associated with bone metasta-
ses, including debilitating pain, fractures and 
hypercalcaemia. However, they do not target the 
tumorigenic process and only inhibit osteoclast 
function and osteoclastogenesis. Approximately 
half of patients continue to develop new bone 
metastases, and breast cancer patients who 
develop pathological fracture have a 32% 
increased risk of death compared to those who 
do not [13, 14]. Therefore, novel therapies aimed 
at recently identified targets are required to influ-
ence both the metastatic tumour cells and the 
bone environment.
It is vital to understand the molecular and cel-
lular events involved in bone modelling and 
remodelling and the effects tumour cells have on 
the skeleton and vice versa. The key cells, osteo-
clasts and osteoblasts, from their two distinct lin-
eages, haematopoietic and mesenchymal 
respectively, were heavily investigated in the 
1980s and 1990s to elucidate their roles in bone 
remodelling, after Epker and Frost (1965) [15] 
demonstrated an interaction between these cru-
cial cells in the remodelling process. This resulted 
in the subsequent identification of a trio of key 
molecules in the 1990s, receptor of activator of 
NF-κB (RANK), RANKL and osteoprotegerin 
(OPG), whose interplay is fundamental to the 
regulation of bone homeostasis [16–18]. Since 
then, these molecules have been under intense 
investigation in bone-related conditions, includ-
ing bone metastases.
9.2  OPG, RANK and RANKL 
in Bone Metastasis 
Associated with Breast 
Cancer
RANKL, its receptor RANK and its naturally 
secreted decoy OPG are all members of the TNF
receptor superfamily. Originally linked to bone 
remodelling and immunity, they have since been 
extensively studied in a wide range of solid can-
cers, including breast cancer, particularly focus-
ing on their effects on the bone microenvironment. 
Furthermore, recent studies in breast cancer have
shown that these bone-related molecules could 
be potential prognostic and therapeutic targets 
beyond the bone.
9.2.1  RANK/RANKL Signalling 
in Mammary Gland 
Development 
and Carcinogenesis
In the last decade, the RANK/RANKL pathway 
has come to prominence in breast cancer research 
beyond the bone environment due to several key 
observations. RANK and RANKL along with 
several hormones, including sex hormones, pro-
lactin and PTHrP, have been linked with both 
normal mammary gland development and lacta-
tion, including ductal side branching, alveolar 
differentiation and lumen formation during preg-
nancy and carcinogenesis [19–22]. The interac-
tion of progesterone and RANKL signalling has 
been particularly relevant given that this can 
occur in both progesterone-positive and 
progesterone- negative cells. In progesterone- 
responsive luminal cells, RANKL is upregulated, 
which helps stabilise RNA. Furthermore, evi-
dence has shown that through paracrine RANKL 
signalling on oestrogen and/or progesterone 
receptor-negative breast cancer cells, prolifera-
tion can also be induced [23–27].
Further evidence has shown that RANK loss
or overexpression contributes to disrupted mam-
mary gland development and impaired lactation 
during pregnancy [28]. Furthermore, RANK has
been shown to promote proliferation and survival 
of mammary epithelial cells as well as expansion 
of mammary stem and luminal progenitor cells 
[29]. Thus, RANK signalling, through enhanced 
activation of protein kinase B (PKB/AKT) and 
extracellular signal-related kinase (ERK) 1/2, 
causes mammary progenitor populations, which 
are potentially supported by the paracrine signal-
ling of RANKL, in either its membrane bound or 
soluble forms, to promote breast tumour forma-
tion [30].
Beyond the role that RANK/RANKL signal-
ling plays in mammary gland development, Blake 
et al. [31] demonstrated that MDA-MB-231 
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breast cancer cells overexpressing RANK 
resulted in greater bone colonisation and growth. 
Furthermore, Casimiro et al. [32] identified that 
RANK expressing bone-seeking subclones of 
MDA-MB-231 cells exhibited increased cell 
migration and invasion through RANKL- 
mediated c-jun N-terminal kinase (JNK) and
ERK 1/2 signalling. We have previously demon-
strated that the targeting of RANK expression in 
breast cancer cells in vitro reduced cell-matrix 
adhesion, migration and invasion [33]. Whilst 
Jones et al. [34] reported that mice with RANK 
deletion, specifically in mammary gland epithe-
lial cells, exhibited decreased cell proliferation 
under progesterone stimulation compared to the 
wild-type mice. However, in spite of these obser-
vations, no RANK targeting agents currently 
appear to be in clinical trials for the treatment of 
primary breast tumours.
Denosumab, which targets osteoclastogenesis 
by blocking the actions of RANKL, is effective 
in the treatment of SREs. Literature shows that 
in vitro cocultured breast cancer cell lines devoid 
of RANKL could still stimulate RANKL expres-
sion in stromal osteoblasts, thus driving osteo-
clastogenesis and highlighting the relevance in 
targeting changes which occur in the microenvi-
ronment as well as the tumour cells and their 
related factors [19, 35].
9.2.2  The Pros and Cons of OPG 
in Breast Cancer
Given that OPG is the natural decoy of RANKL 
and a negative regulator of bone metabolism, the 
reversal of its downregulation has been consid-
ered for the treatment of breast cancer-associated 
bone metastasis. Studies have found that basal 
levels of OPG are expressed in breast cancer cells 
and tissues. Van Poznak et al. [36] has further 
demonstrated that in 55% of breast cancer cases 
studied, OPG expression was detected and cor-
related with oestrogen and progesterone recep-
tors. However, subsequent functionality tests 
have suggested a negative correlation between 
OPG and the oestrogen receptor (ER), whereby 
activation of the ER results in a decrease in OPG 
expression. This was demonstrated in the 
ER-positive cell line MCF-7 when it was treated
with 17β-oestradiol, which inhibited OPG at both 
mRNA and protein levels. The effect was reversed 
with the addition of the selective ER downregula-
tor Fulvestrant (ICI-182,780) [37]. OPG also has 
a weak affinity for TNF-related apoptosis induc-
ing ligand (TRAIL), which is believed to aid 
breast cancer cell survival by evasion of death 
receptor-induced apoptosis, as has been demon-
strated in vitro but not in vivo [38]. It may be less 
effective in vivo due to evidence suggesting that 
excessive RANKL can reverse the effect of OPG 
on TRAIL-induced apoptosis [39, 40]. The iden-
tification of OPG in breast cancer and its associ-
ated metastasis in vivo appears mixed, potentially 
due to differing effects between the whole and 
truncated protein versions of OPG and its 
response to other factors such as hepatocyte 
growth factor (HGF) [33, 41–44]. It seems that 
outside of the bone microenvironment, OPG 
might have a tumour-proliferating effect and thus 
be a driver for metastasis to occur in other parts 
of the body [45].
Implications of OPG and breast cancer have 
also been conflicting, potentially due to different 
breast cancer subtypes [44, 46–49]. Therefore, 
OPG as a direct target may not provide the best 
solution for the treatment of breast cancer- 
associated bone metastasis. As Croft et al. high-
lighted in 2013, all clinical trials targeting OPG 
had been discontinued [50]. Perhaps modulation 
of OPG as an indirect consequence of other ther-
apeutic intervention could be beneficial. If it is 
contained to the bone environment, its utilisation 
for breast cancer-associated bone metastasis 
treatment may be more advantageous.
9.3  Targeting Aberrant BMP 
Signalling in Bone 
Metastasis of Breast Cancer
Bone morphogenetic proteins (BMPs) belong to 
the TGF-β superfamily which play pivotal roles 
in embryonic and postnatal development as well 
as the homeostasis of tissues and organs by coor-
dinating differentiation, proliferation, apoptosis 
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and motility of cells in tissue and organ-specific 
structures. BMP signalling is relayed through a 
heteromeric receptor complex comprising two 
types of serine-threonine kinase transmembrane 
receptors. Type I receptors mediating BMP sig-
nalling include activin receptor-like kinase-1 
(ALK-1), BMP receptor type IA (BMPR-IA, also 
known as ALK-3), BMP receptor type IB 
(BMPR-IB, or ALK-6), ALK-4, ALK-5 and
activin A receptor type I (ActRI). The type II 
receptors include BMP receptor type II 
(BMPR-II), activin A receptor type IIA (ActRIIA) 
and activin A receptor type IIB (ActRIIB). Upon
binding of BMP ligands, the type II receptors 
phosphorylate the glycine-serine (GS) domain of 
type I receptors, leading to the recruitment of the 
pathway-restricted Smads (R-Smads, Smads1, 5 
and 8) to the complex. With assistance from 
Smad 4, the R-Smads intracellular signalling
complex is translocated into the nucleus, leading 
to the induction of BMP-responsive genes. 
Smads 6 and 7 negatively regulate this Smad- 
dependent signalling. On the other hand, the 
Smad-independent pathways, such as mitogen- 
activated protein kinase (MAPK) pathway and 
the RAS pathway, also relay signals into cells. 
Thus, these diverse pathways orchestrate cellular 
responses to BMP ligands [51].
As a group of important regulators for bone 
formation and turnover, the possible implication 
of these proteins in bone metastasis of certain 
solid tumours has been investigated [51]. The 
attention to BMPs and their role in breast cancer 
arose nearly a decade ago, with a number of key 
findings being made in this area.
9.3.1  Aberrant Expression of BMPs 
in Breast Cancer
Our previous studies have shown that expression 
of BMPs, including BMP-2, BMP-4, BMP-6,
BMP-7, BMP-12, BMP-15 and GDF9a, is
reduced in breast cancer. The decreased expres-
sion of BMP-2, BMP-7, GDF9a and BMP-15 is
associated with poor prognosis [52–54], which 
has also been found in other studies [55, 56]. 
BMP-7 is reduced in primary tumours with bone 
metastasis [57]. However, other studies have 
linked overexpression of BMP-2, BMP-4, BMP-5
and BMP-7 with breast cancer [52, 58–61]. These 
contrasting findings suggest that BMPs may play 
different roles during the development and pro-
gression of breast cancer.
Certain BMP receptors have been assessed for
their involvement in breast cancer. An increased 
expression of BMPR-IB has been observed in 
poorly differentiated tumours, with a higher rate 
of proliferation and cytogenetic instability. The 
overexpression of BMPR-IB was also associated 
with poor prognosis in ER-positive carcinomas 
[62]. This suggests that the expression of this 
type I receptor may be associated with the ER 
status and is regulated by oestrogen. Moreover, 
our previous study in a breast cancer cohort from 
the University Hospital of Wales showed that a
decreased expression of BMPR-IB was associ-
ated with poor prognosis [63]. Differences in the 
ER status may be a reason for these conflicting 
findings. Activated Smad1/5/8 and Smad 2 were 
observed in nuclei of breast cancer cells from 
both primary tumours and bone metastases. This 
is supported by findings from an in vivo murine 
model [64]. TGF-β3 and BMP-2 promoted inva-
sion of MDA-231-D cells, where a blockage of 
the TGF-β and/or BMP signalling by expression 
of domain-negative receptors eliminated the 
TGF-β3- and BMP-2-induced invasion and TGF-
β3- and BMP-2-associated bone metastasis. It 
suggests that BMPs and TGF-ß may synergisti-
cally work together to promote the invasion and 
bone metastasis of breast cancer [64].
9.3.2  Regulatory Aspects of BMP 
Signalling
The diversity of BMP expression and signalling 
occurs in malignancies throughout their develop-
ment and progression, reflecting the temporal and 
contextual nature of BMP influence. The addi-
tional complexity is both the regulatory machin-
ery for BMPs and their interactions with other 
factors. A number of hormones and growth fac-
tors have been indicated within the BMP signal-
ling networks.
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9.3.2.1  Crosstalk with Oestrogen 
Receptor Signalling
Hormone receptor status may have great influ-
ence on aberrations in BMP phenotype and sig-
nalling with self-adjustment by tumour cells 
themselves, according to their needs for devel-
opment and progression at different stages. 
Indeed, epigenetic regulation of BMPs and 
BMPRs in breast cancer is associated with ER 
status [65]. Oestrogen represses the expression 
of BMPR-IA, BMPR-IB, ActRIIA and ActRIIB 
but not ActRI and BMPR-II [66]. The expres-
sion of BMP-7 has been found to highly cor-
relate with the expression levels of ER, 
although BMP-7 expression is reduced in 
response to oestrogen [67, 68] and BMP-2 
expression is significantly higher in 
ER-negative tumours [69].
Oestrogen and BMPs can influence each oth-
er’s function through interactions between recep-
tors and downstream signalling [70, 71]. For
example, oestrogen interferes with the biological 
function of BMP-2 by inhibiting the activation of 
Smad, as a result of biochemical interaction 
between Smad and ER [70]. Conversely, BMP
signalling can affect ER function, as Smad 4 pre-
vents the transcriptional regulation mediated by 
cytoplasmic ER [71], and BMP-2 inhibits 
oestradiol- induced proliferation of ER-positive 
breast cancer cells via upregulation of cyclin 
kinase inhibitor p21, which in turn inhibits the 
oestradiol-induced cyclin D1-associated kinase 
activity [72].
Hypermethylation of BMP-6 and its reduced 
expression have been observed in ER-negative 
breast cancer tissues [65]. Methylation of the 
BMP-6 gene promoter has been detected in 
ER-negative cell lines, whilst in ER-positive 
cells, the BMP-6 gene promoter remains demeth-
ylated. Studies show overexpression of BMP-6 
particularly in ER-positive cell lines and tumour 
samples [65, 73]. Further in vitro study has dem-
onstrated the interaction of ER with sites on the 
BMP-6 promoter region [65]. This suggests that 
ER status is linked with BMP expression at epi-
genetic level.
9.3.2.2  Crosstalk with Androgen 
Receptor Signalling
In breast cancer, the androgen receptor (AR) has 
received increasing attention related to treatment 
resistance, and its expression has been linked to 
both good and poor prognosis [74]. In tumours 
responsive to neoadjuvant endocrine therapy, AR 
mRNA and protein expression is decreased, 
whilst this is not seen in treatment-resistant 
tumours. In a clinical cohort, a high AR/ER ratio 
was shown as an independent risk for failure of 
tamoxifen treatment and poor survival. The find-
ing has been corroborated by both in vitro and 
in vivo studies on breast cancer models, whereby 
AR overexpression is shown to increase tamoxi-
fen resistance [75]. The underlying mechanisms 
regarding interactions between BMP signalling 
and AR are not yet clear in breast cancer. 
However, it would be a novel area to explore for 
possible targeted therapy particularly for endo-
crine treatment-resistant breast cancers.
9.3.2.3  Crosstalk with Growth Factor 
Signalling
Several other factors and pathways have been 
indicated in the regulation of BMP expression 
and function. BMP-4 generally inhibits breast
cancer cell growth but enhances proliferation of 
breast cancer cells induced by fibroblast growth 
factor (FGF), epidermal growth factor (EGF) and
HGF [76]. EGF treatment of breast cancer cells
in vitro upregulates BMP-4 signalling, leading to
suppression of matrix metalloprotease (MMP) 9. 
This effect was reduced when treated with 
BMP-4 antagonists Gremlin or Smad 6 [77]. In 
addition, BMP-6 in breast cancer cells can be 
upregulated by EGF and other EGF receptor
(EGFR) ligands [55]. Conversely, EGF-, FGF-
and HGF-activated MAPK/ERKs phosphorylate
a linking region of Smad1/5/8, resulting in 
reduced nuclear translocation and transcription 
of BMP target genes [78, 79]. BMPs also exert 
reciprocal effects, suppressing EGF-induced
gene transcription through MAPK/ERK-1 sig-
nalling [80]. BMP-9 decreases human epidermal 
growth factor receptor 2 (HER2) expression, 
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inactivating ERK1/2 and phosphoinositide 
3-kinase (PI3K)/AKT signalling pathways and 
leading to reduced proliferation and metastasis of 
SK-BR-3 breast cancer cells [81].
There is also interaction between Wnt and 
BMP signalling. SOSTDC1, a secreted regulator
of both pathways, is under-expressed in breast 
cancer tissue and breast cancer cells. SOSTDC1
increases Wnt3a signalling and decreases BMP-7 
signalling whilst eliciting little effect on BMP-2- 
induced signalling [82].
Nacamuli et al. demonstrated that BMP-3 
expression can be controlled by recombinant 
human FGF in calvarial osteoblasts [83]. Retinoid 
has been shown to induce expression of BMP-2 in 
the retinoid-sensitive cell lines [84]. Rapamycin 
induces BMP-4 and downregulates BMP antago-
nist Follistatin expression in a prostate cancer
cell line (PC3) [85]. Our previous studies showed 
that HGF upregulated the expression of BMP-7
and BMP receptors in prostate cancer cells. 
These upregulations were blocked by NK4, an
antagonist of HGF [86, 87]. HGF-regulated BMP
and BMP signalling may form a part of its contri-
bution to the disease progression and bone metas-
tasis. These studies collectively indicate that 
BMPs, together with other growth factors, form a 
collaborative interacting network during the 
development and progression of cancer, which 
would be worthy of further study, particularly 
given how important receptor status has become 
in breast cancer prognosis and treatments.
9.3.3  BMP Signalling 
in the Predisposition 
of Metastasis to Bone 
and Formation of Osteolytic 
Lesions
BMPs are the most powerful bone inductive fac-
tors which are abundant in bone matrix. In a bone 
metastatic lesion, BMPs can be synthesised by 
osteoblasts and stored in bone matrix. In addi-
tion, cancer cells can release BMPs and their 
antagonists to coordinate their functions. Secreted 
from cancer cells, BMPs contribute to bone 
lesion by targeting bone cells and in turn enhance 
aggressiveness of cancer cells. BMPs can also 
indirectly support the colonisation and develop-
ment of bone metastasis by promoting tumour- 
associated angiogenesis, which makes them key 
factors in the ‘vicious cycle’ of bone metastasis. 
Both clinical and experimental studies have sug-
gested profound roles for BMPs in the bone 
metastasis of breast cancer.
9.3.3.1  Profile of BMPs in Bone 
Dissemination 
and the Metastatic Bone 
Microenvironment
Decreased expression of BMP-7 in primary 
tumours correlates with bone metastases, whilst 
BMP-7 is capable of inhibiting the growth of 
breast cancer tumours in bone in vivo [57]. Other 
studies have shown BMP-7 overexpression in 
primary tumours is associated with bone metasta-
ses [68]. In murine 4T1E/M3 mammary cells,
which are highly metastatic to bone, expression 
of BMP-7, BMPR and phosphorylated Smad1/5/8 
are upregulated. These highly invasive features 
are attenuated when BMP-7 is inhibited [57].
Other studies have found that BMP-induced 
transcriptional pathways are active in bone meta-
static lesions in vivo, and xenograft tumours with 
dominant negative BMP receptors have fewer 
bone metastases [64].
BMP-9 suppresses the growth of breast 
tumour cells in bone, mediated by BMP-9- 
induced downregulation of connective tissue 
growth factor (CTGF) [88, 89]. Orthotropic 
implant of tumours with silk scaffolds coupled 
with BMP-2 and seeded with bone marrow stro-
mal cells (BMSC), contributed to bone metasta-
sis of breast cancer cells in vivo [90].
Breast cancer cells themselves can display an 
osteoblast-like phenotype by expressing bone 
matrix proteins such as bone sialoprotein (BSP), 
osteopontin (OPN), OPG and osteoblast-specific 
cadherins [91–93]. Breast cancer cells with 
induced epithelial-to-mesenchymal transition 
(EMT) exhibited an elevated level of bone-related 
genes (BRGs) and osteoblast-like features when 
exposed to BMP-2. Breast cancer cells express-
ing these BRGs favoured spread and survival in 
the bone. Interestingly, the cells were also more 
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resistant to chemotherapy [93]. The BMP antago-
nist Noggin reversed these effects, as did 
 knockdown of runt-related transcription factor 2 
(RUNX2), which regulates bone remodelling and
osteogenic differentiation [68, 93, 94]. This 
‘bone signature’ induced by BMPs may be one of 
the reasons breast cancer cells home to bone tis-
sue. Once the breast cancer cell is established in 
the bone, BMPs and their antagonists continue to 
influence survival of the tumour within the micro-
environment [95].
9.3.3.2  Regulation of BMPs in Bone 
Microenvironment
Local factors such as sexual hormones may play 
a role in regulation and adaptable expression of 
BMPs in bone metastases. The selective oestro-
gen receptor modulator (SERM) raloxifene 
increases BMP-4 promoter activity in U-2 OS
osteoblast-like cells. ER is thought to be indis-
pensable for this effect [96]. In addition, oestra-
diol enhances BMP-4-induced expression of
osteoblastic markers (RUNX2, osterix, osteocal-
cin) in osteoprogenitor cells [97].
In osteoblasts, BMP-6 reporter activity is 
increased with antioestrogen treatment and 
decreased with oestradiol treatment, which pro-
vides evidence that ER regulates BMP-6 differ-
entially in the breast and bone. Patients with 
ER-positive breast tumours are more likely to 
develop skeletal metastases [73], and this interac-
tion between ER and BMP signalling may be the 
key influence on skeletal secondary formation in 
breast cancer.
BMP antagonists also appear to have a signifi-
cant role in bonemetastasis. Conditionedmedium
(CM) from breast cancer cells (HT-39) resulted
in upregulation of BSP mRNA expression in 
osteoprogenitor cells (MC3T3-E1 cells) and a
promotion of their osteoblastic behaviour. This 
effect was blocked by the addition of BMP antag-
onist Noggin [98]. High expression levels of 
Noggin are associated with bone metastases in 
both cell line/murine models and clinical samples 
of breast cancer bone metastases [99]. 
Upregulation of Noggin and another antagonist
Follistatin, by zinc finger E-box-binding homeo-
box 1 (ZEB1) in breast cancer cells, induces dif-
ferentiation of osteoclasts in vitro, which suggests 
an osteolytic influence in the bone microenviron-
ment [100].
Another recent study has also demonstrated 
that lack of Noggin expression in both breast and 
prostate cancer cells is associated with osteoblas-
tic activities in bone metastases. Overexpression 
of Noggin in an osteo-inductive prostate cancer 
cell line (C4-2B) inhibited osteoblastic activities
but had little effect on bone resorption and tumour 
growth [101]. BMPs and their antagonists evi-
dently play a role in coordinating the osteoblastic 
and osteolytic activities in bone metastatic lesions 
and thus necessitate further study, particularly in 
regard to therapeutic potential.
9.3.4  Therapeutic Potential 
of Targeting BMPs
We require agents that act to prevent or resolve 
bone metastasis, and in this respect, BMPs/
BMP antagonists are largely underexplored. 
Both clinical and experimental studies suggest 
profound potential for targeting BMPs in treat-
ing breast cancer and bone metastasis. BMPs 
not only directly affect cancer cells to coordi-
nate their abilities during disease progression 
and bone metastasis but also indirectly contrib-
ute to bone metastasis through regulating 
tumour-related angiogenesis and the bone 
microenvironment.
In an in vivo bone tumour model, exposure of 
tumour-bearing subjects to Noggin, an antagonist 
of BMPs, reduces the size of bone lesions by a
mechanism that involves both osteoblastic and 
osteolytic processes. The BMP antagonists, 
Noggin and Follistatin, are also determining fac-
tors of the cells response to BMPs. Expression of 
these antagonists can be regulated by BMPs 
themselves probably through an autocrine or 
paracrine feedback loop. A good example is 
BMP-7, whose endogenous expression is inti-
mately linked to the levels of Noggin and 
Follistatin in the same cell [102]. These findings 
collectively indicate the value of BMPs and their 
antagonists in the management of tumour pro-
gression and bone metastasis.
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9.3.4.1  BMP Receptor Inhibitors
The BMP type I receptor small molecule inhibi-
tors dorsomorphin and LDN 193189 have been 
used in several breast cancer studies to abrogate 
BMP signalling, appearing to reverse stemlike 
features in breast cancer cells and reduce inva-
siveness. Their clinical testing is yet to be further 
developed, and targeting the pathway down-
stream of the receptors still needs to be explored.
However, clinical trials are already underway 
for blocking ALK-1. ALK-1 inhibitors block the 
interaction of BMP-9 and BMP-10 with ALK-1, 
interrupting the subsequent intracellular signal-
ling pathway. PF-03446962 is an ALK-1-specific
neutralising antibody currently being evaluated 
in Phase II trials for solid tumours as an anti- 
angiogenic treatment [103]. Dalantercept is a 
soluble chimeric ALK-1 receptor-like protein 
(ALK1-Fc), which displays high-affinity binding
with BMP-9 and BMP-10, resulting in inhibition 
of angiogenesis and suppression of tumour 
growth [104]. Initial studies showed that 
ALK1-Fc decreased metastasis formation in a
breast cancer model [105]. In mice, treatment 
with ALK1-Fc seemed to remodel tumour vascu-
lature, with increased perfusion and reduced 
hypoxia. A temporary improvement of tumour 
perfusion could result in a better delivery and 
efficacy of chemotherapy. Indeed, pretreatment 
with ALK1-Fc allowed tumours to be more sen-
sitive to cisplatin, which could repress disease 
progression [104].
9.3.4.2  BMP/DKK1 Inhibitors
Within the bone environment, Dickkopf 1 
(DKK1) is a downstream molecule of BMP sig-
nalling that inhibits canonical Wnt signalling and 
therefore negatively regulates bone mass. Tumour 
production of DKK1 is thought to contribute to 
osteolytic bone lesions [14, 106]. A DKK1- 
neutralising antibody is in clinical trials for mul-
tiple myeloma. Bortezomib is a proteasome
inhibitor which inhibits osteoclast formation and 
bone resorption whilst enhancing osteoblastic 
differentiation and mineralisation in vitro. The 
detailed mechanisms are unclear but may result 
from decreased DKK1. The fact that BMP sig-
nalling acts upstream makes BMP antagonism 
and interaction with Wnt signalling a future area 
of exploration for bone metastases therapeutics 
[14, 107].
9.3.4.3  mTOR Inhibitors
Another area of therapeutic interest more recently 
is the PI3K-Akt-mechanistic target of rapamycin 
(mTOR) pathway – a key mediator of cellular 
proliferation, apoptosis, migration and angiogen-
esis, which is commonly activated in breast can-
cer, conferring resistance to hormonal therapy 
and trastuzumab. In breast cancer models, BMP-2
induces PI3K in osteoblasts to regulate differen-
tiation. Blocking the PI3K-Akt-mTOR pathway 
suppresses RANKL and increases OPG secretion 
by the bone marrow stroma, which reduces osteo-
clast activity. mTOR inhibitors are part of ongo-
ing trials regarding hormone receptor-positive, 
treatment-resistant tumours. The relationship of 
BMPs with this pathway and the apparent 
involvement of PI3K/mTOR in the bone provide 
intriguing prospects for the treatment of bone 
metastasis [108, 109] .
9.4  Activated Leukocyte Cell 
Adhesion Molecule (ALCAM) 
in Bone Metastasis
Current projects within our laboratories have
highlighted a number of proteins and pathways 
involved in regulating metastatic characteristics 
and their potential importance in the develop-
ment of bone metastasis. One such candidate is 
activated leukocyte cell adhesion molecule 
(ALCAM).
9.4.1  Discovery 
and Characterisation 
of ALCAM
Bowen et al. first identified and characterised 
ALCAM in 1995 and subsequently mapped it to
chromosome 3q13.1–q13.2 [110]. ALCAM has
been reported to be identical to MEMD, a cell 
adhesion molecule found to be preferentially 
expressed in metastasising melanoma cell lines 
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compared to non-metastasising lines [111]. 
ALCAM, also known as CD166, is a member of
the immunoglobulin superfamily and is involved 
in mediating homophilic (ALCAM-ALCAM)
and heterophilic (ALCAM-CD6) interactions
[110, 111]. Members of this family are character-
ised by the presence of five NH2 terminals, extra-
cellular immunoglobulin domains comprising 
two membrane distal variable (V)-type folds and 
three membrane proximal constant (C2) folds, a
transmembrane region and a short cytoplasmic 
region [112]. The membrane distal domain 1 
appears to be important for homophilic binding, 
whilst the membrane proximal (C2 fold) domain
4 and 5 appear to be important for avidity and
ALCAM clustering on the membrane [112, 113]. 
As with other cell adhesion molecule, ALCAM
has been linked with a number of physiological 
functions but has also been implicated in cancer 
progression, attracting considerable scientific 
attention.
9.4.2  Metastatic Potential of ALCAM 
and Clinical Implications 
in Breast Cancer
The role played by ALCAM in cancer progres-
sion appears to be highly complex. Despite sig-
nificant research into its expression profile in 
cancer progression, it still remains unclear as to 
the precise function or expressional alterations of 
ALCAM in cancer progression. One factor
potentially influencing this complexity is the 
capacity for ALCAM to exist at a number of cel-
lular and extracellular locations. None the less, 
there are many contrasting reports highlighting 
the prognostic potential of ALCAM expression.
Such examples, focusing on cellular expression 
of ALCAM in breast cancer reports, have been
summarised in Table 9.1, though similar observa-
tions are made within a number of other cancer 
types as well. Hence, it is apparent from such 
studies that ALCAM plays a significant, if some-
what unclear, role in breast cancer progression, 
and with further understanding, it could hold 
potential as a biomarker or therapeutic strategy. 
The potential of ALCAM as a prognostic factor is
also strengthened due to the capacity of a shed/
secreted form being detectable in patient serum. 
ALCAM can be proteolytically shed into the sur-
rounding extracellular environment by proteases 
such as A disintegrin and A metalloproteinase 17/
tumour necrosis factor-alpha-converting enzyme
(ADAM17/TACE) [114]. Unlike cellular
ALCAM, a clear trend has emerged within the
literature, and elevated serum ALCAM has been
detected in breast cancer patients. Serum 
ALCAM has also been shown to be enhanced in
higher-grade breast cancers, and current data 
indicates it may be a more suitable serum marker 
than the current established markers, CA15-3
and CEA in breast cancer [115–117].
A number of cell-based studies have also 
explored the functional significance of ALCAM
in breast cancer cell lines. ALCAM has been sug-
gested as an important player in programmed cell 
death and apoptosis. A previous study has identi-
fied a protective effect of ALCAM against pro-
grammed cell death in breast cancer cells and 
demonstrated that the overexpression of BCL2
could enhance ALCAM expression and induce
apoptosis/autophagy following the silencing of 
ALCAM. Furthermore, the study highlighted that
ALCAM expression might be inhibited by
tamoxifen and enhanced by 17-β oestradiol in 
MCF-7 cells [118]. A further study characterised 
ALCAM in MDA-MB-231 and MCF-7 breast
cancer cell lines and generated knockdown and 
overexpression models, respectively. The study 
did not detect any differences in growth rates of 
such cells, though ALCAM did appear to influ-
ence apoptosis. The study also described an 
enhanced migratory potential of ALCAM-
suppressed MDA-MB-231 cells and, in keeping, 
a reduced level of migration in MCF-7 cells over-
expressing ALCAM. However, the invasive
potential of MDA-MB-231 knockdown cells was 
reduced, and no significant impact on invasion 
was shown in the MCF-7 overexpression line
[119]. Another study isolated a human monoclo-
nal antibody, recognising ALCAM (scFv173),
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Table 9.1 Potential prognostic implication of ALCAM expression in clinical breast cancer tissues
Key finding/prognostic value References
IHC and qPCR analysis was used to examine ALCAM expression in breast cancer (n = 120) and 
normal breast (n = 32) tissues. Stronger membranous and cytoplasmic ALCAM staining intensity
were seen in normal tissue compared to breast tumour tissue. Transcript analysis suggested slightly 
higher ALCAM levels in tumour vs. normal breast samples. Low ALCAM transcript analysis in
primary tumour was associated with higher grade and NPI stage, nodal involvement, local recurrence, 
death due to breast cancer and poorer disease-free survival
[129]
IHC staining of breast carcinomas (n = 162) indicated higher ALCAM expression in invasive and
intraductal cancers compared to normal breast tissues. High ALCAM cytoplasmic staining was
associated with reduced patient disease-free survival times and earlier disease progression. High 
ALCAM membranous staining was associated with reduced overall patient survival
[130]
Laser scanning cytometry and confocal microscopy analysis of breast cancer samples (n = 56) 
indicating high ALCAM expression was significantly correlated with small tumour diameter, low
grade and oestrogen and progesterone receptor positivity. Low ALCAM expression tended to
associate with HER2 amplification. ALCAM/MMP-2 ratio may hold potential indicator of
progression, with higher ratios seen in low-grade and small tumour diameter samples
[131]
ALCAM protein (n = 160) and mRNA (n = 162) expression in primary mammary carcinomas was 
analysed. ALCAM protein expression correlated with ER status. In patients treated with adjuvant
chemotherapy, high ALCAM protein expression was generally associated with longer disease-free
and overall survival, and this observation was more apparent at the mRNA level, where the 
association with overall survival was significant. Cox regression analysis indicated high ALCAM
mRNA was a predictor of longer overall survival in chemotherapy-treated patients
[132]
IHC and qPCR analysis were used to assess ALCAM expression in primary breast cancer (n = 243)
and non- neoplastic mammary tissues (n = 34). ALCAM staining was reduced in cancerous tissue and
tissue from patients who developed skeletal metastasis compared to normal tissues. Lower ALCAM
transcript expression was also associated with poorer patient prognosis, poor NPI, local recurrence, 
metastasis, skeletal metastasis and death
[124]
IHC analysis of FFPE tissues from 29 autopsy cases (primary n = 25 and related distant metastasis 
n = 84) demonstrated that ALCAM staining intensities in primary tumour and metastasis of the same
patient were similar, and ALCAM expression in the primary tumour was prognostic for ALCAM
staining in metastasis of the patient
[133]
mRNA analysis of ALCAM, osteopontin, HER2 and ER in breast cancer tissues (n = 481) identified
that in low or negative HER2/ER samples, high osteopontin and low ALCAM transcript expression
aided in identification of high-risk patients with shorter disease- free and overall survival rates
[134]
IHC staining on breast cancer patient samples (n = 347) demonstrated ALCAM was associated with
oestrogen and progesterone receptor status. ALCAM overexpression significantly correlated with
nodal involvement and tended to be associated with the presence of disseminated tumour cells in the 
bone marrow. Strong ALCAM expression also correlated with reduced recurrence and overall
survivals in ductal carcinomas
[119]
Significant association was noted between ALCAM polymorphism (rs6437585T > C in ALCAM
promoter) and risk of developing breast cancer in a Chinese population
[135]
IHC ALCAM staining intensity in tissue obtained from breast cancer metastasis (n = 117) was found 
to be higher in skin metastasis than in any other metastatic tissues examined (bone, liver, brain and 
lung), and ALCAM staining was also found to be higher in primary tumours which metastasised to
the skin
[136]
Protein analysis of ALCAM expression in breast cancer patients (n = 150) indicated high expression 
of ALCAM at the membrane was associated with metastatic dissemination and lymph node
metastasis, whereas increased ALCAM expression in the cytoplasm was associated with short-term
local recurrence and shortened disease-free patient survival
[137]
Two SNPs within the ALCAM gene (re1044243 and rs1157) were associated with breast cancer-
specific survival when analysed in a Swedish population-based series (n = 783) of breast cancer 
cases. However, no association was observed within a Polish population of familial/early-onset breast 
cancer cases (n = 506)
[138]
(continued)
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which could bind ALCAM on both cancer cell
lines and in tumour tissues. It reported that the 
addition of scFv173 could inhibit the invasive
potential of MDA-MB-231 in vitro and reduce 
tumour development of a colorectal carcinoma 
cell line (HCT116) in vivo [120].
To further understand the role of ALCAM in
breast cancer, a number of studies have explored 
the potential mechanisms responsible for control-
ling ALCAM expression. King et al. have
reported that DNA methylation of the ALCAM
promoter is one such mechanism influencing 
ALCAM expression and that this may be signifi-
cant factor in regulating ALCAM expression in
tumour tissue. Furthermore, such a loss may
inhibit adherence between circulating tumour 
cells, therefore supporting a role for ALCAM
loss in enhancing metastatic potential [121]. 
Recently, the regulation of ALCAM expression
by microRNAs has been reported in breast can-
cer. ALCAM was found to be one of a panel of
genes whose expression was altered following 
expression of miR-125b. Expression of miR- 
125b enhanced both ALCAMmRNA and protein
levels, which was found to influence MCF-7
growth using a further shRNA study [122]. It has 
also recently been reported that inhibition of 
miR-214, overexpression of miR-148b or a com-
bination can inhibit tumour cell crossing of the 
vessel endothelium through a negative regulation 
of ALCAM and integrin α5 [123].
9.4.3  Potential Role for ALCAM 
in Bone Metastasis
Though complex, the literature supports a role 
for ALCAM in the progression and metastatic
dissemination of cancer. To elucidate the poten-
tial of ALCAM in influencing the development
of bone metastasis, our laboratories further 
explored ALCAM in a larger, combined breast
cancer cohort and examined the association 
between ALCAM expression and the develop-
ment of bone metastasis [124]. In keeping with 
our previous findings, through immunohisto-
chemical analysis, lower ALCAM cytoplasmic
expression was noted in breast cancer tissues and 
in tissue sections from patients who went on to 
develop skeletal metastasis compared to normal 
breast tissue. Furthermore, quantitative PCR
analysis similarly indicated that significantly 
lower ALCAM transcript expression was associ-
ated with patients with poorer prognostic indica-
tors and that low ALCAM expression was
associated with those patients who went on to 
develop skeletal metastasis. This trend was simi-
larly observed when focusing on ductal carci-
noma cases alone [124]. To further explore this 
potential link, our laboratories examined 
ALCAM overexpression and knockdown models
in MDA-MB-231 and ZR-751 cell lines, respec-
tively, and explored the in vitro impact of cultur-
ing such cells in the presence of a bone matrix 
Key finding/prognostic value References
IHC analysis of ALCAM in 173 cases (African American n = 78 and Caucasian n = 95) of breast 
cancer indicated that, in both ethnic groups, lower ALCAM expression at intercellular junctions
correlated with grade, ER, PR and triple negative status and contributed to a more aggressive 
phenotype. Ethnicity also significantly contributed to ALCAM expression after accounting for other
factors, with the African American group more likely to have low ALCAM expression than the
Caucasian ethnic group
[139]
IHC analysis of TMA (n = 2197) demonstrated membranous ALCAM expression in both normal and
cancerous breast tissues. A decreased expression of ALCAM was found to be associated with
negative ER and PR status, high Ki67 index, advanced tumour size and grade and cancers with loss
of ALCAM expression resulted in significantly poorer disease-free and overall survival rates
[140]
IHC analysis of primary ER-positive breast cancer tissues from tamoxifen responders (n = 16) and 
nonresponders (n = 20) suggested higher ALCAM staining in the nonresponders
[141]
Table 9.1 (continued)
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extract (BME) generated from ground and soni-
cated femoral heads. Such experiments high-
lighted a role for ALCAM expression in
negatively regulating cell growth and matrix 
adhesion and migration and underscored a poten-
tial relationship between ALCAM expression
and the responsiveness of MDA-MB-231 cells to 
the bone extract, particularly in terms of growth 
and migratory responses where ALCAM overex-
pression in the presence of bone matrix extracts 
brought about greater reductions in such traits 
[125]. Taken together, these two studies by 
Davies et al. suggest a potential inhibitory role 
for ALCAM in the development of bone metasta-
sis. However, an additional study by Hein et al. 
examining ALCAM immunostaining in a tissue
microarray suggested that high ALCAM staining
correlated with ER positivity, nodal involvement 
and the presence of disseminated tumour cells 
within the bone marrow environment. 
Furthermore, alteration of ALCAM levels in
MDA-MB-231 and MCF-7 cells caused differen-
tial expression of a number of molecules includ-
ing cathepsin D and RUNX2 [119], both of which 
have implications in bone malignancies and 
metastasis [126, 127]. Further evidence support-
ive of a regulator role for ALCAM in bone dis-
semination was recently reported in a study by 
Hansen et al. in a prostate cancer model [128]. In 
their study, Hansen et al. reported that the shed-
ding and detection of tumour-derived ALCAM
was significantly elevated in tumour-bearing 
mice and that reduced ALCAM levels could sig-
nificantly reduce the incident and metastatic bur-
den of bone metastasis following intracardiac 
seeding of cells [128].
Given the significant impact of metastatic 
dissemination and establishment of tumour 
cells in the bone on patient well-being and ulti-
mately survival, there is a great need to identify 
and utilise the responsible mechanisms for the 
development of new therapeutic strategies. 
ALCAM, a molecule linked to cancer progres-
sion and metastasis, though in a somewhat 
complex fashion, represents an interesting 
example of one such novel strategy. From early
indications, ALCAM is likely to play a role in
cancer cell metastasis and development in the 
bone environment, though additional work is 
required to further determine the effect of this 
molecule on this process. Furthermore, the
detection of secreted or shed ALCAM in the
serum of cancer patients may potentially pres-
ent a relatively non-invasive biomarker to mon-
itor patients. Therefore, further large-scale 
study is required to identify and utilise the full 
potential of ALCAM to monitor cancer dissem-
ination to the bone.
9.5  Concluding Remarks
Targeting bone-associated molecules in the 
treatment of breast cancer-associated metasta-
ses is not a simple or quick fix. With such a 
rich and diverse environment for molecular 
targets, opportunities to target bone metastasis 
are vast. Consideration has been given to treat
breast cancer patients in the first-line treatment 
with denosumab, in the hope of targeting any 
breast cancer cells which have already become 
resident in the bone environment. However, 
such a sledge hammer approach is not sustain-
able in the long term, as potentially identified 
targets such as OPG have demonstrated that 
the anti-tumorigenic benefits it exert on one 
area of the body may result in detrimental 
effects elsewhere. Therefore, ongoing efforts 
are essential for seeking factors which could 
identify patients at greatest risk of developing 
bone metastasis or a serum marker which could 
provide insight into the development of bone 
metastasis. The answers may not lie in classi-
cally identified molecules but in newly identi-
fied agents such as miRNAs or emerging 
regulators such as ALCAM. Complete elucida-
tion of the molecules associated with the devel-
opment of breast cancer-associated bone 
metastasis, their interactions and effects on the 
bone microenvironment is critical to achieve 
success of developing any future prognostic 
and therapeutic approach.
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